In boys but not girls, reduced sleep duration at age 8 and 10 years predicted the development of behavioral disorder symptoms 2 years later.
All articles by Caleb Rans
Symptom reduction was significantly correlated with poor metabolic adverse effects, including weight gain, elevated BMI, and higher total cholesterol.
Researchers conducted a case-control study to examine the associations between polygenic risk scores for schizophrenia and other mental disorders with the development of cannabis use disorder.
The researchers analyzed data from 1649 combat-exposed United States military veterans who were evaluated at a Veterans Affairs facility between 2009 and 2012 after deployment to the wars in Iraq and/or Afghanistan.
Researchers sought to address the possible link between cognitive or mood symptoms and statins.
The researchers found that adults with ASD showed significant impairments in both objective (10 of 17 total outcomes) and subjective (6 of 11 total outcomes) measures of sleep compared with controls.
Overall, no significant relationships between task performance and gray matter volume were observed in the clinical high-risk group.
Comorbid anxiety worsened depressive symptom severity in general and was linked to suicidality.
The study emphasizes the necessity of further research concerning a treatment that is increasingly being legalized and applied to a wide range of medical conditions.
Researchers conducted a multicenter randomized controlled trial of 214 veterans with PTSD from January 2012 through September 2013.
Researchers prospectively studied children and adolescents from various outpatient settings in Vienna, Austria to examine the possible effects of migration on mental health.
Response to treatment for negative symptoms was greater in patients in the tDCS arm compared with patients in the sham arm at weeks 6 and 12 (both P <.001).
Researchers conducted a retrospective review to assess the clinical and demographic characteristics of patients with and without rapid cycling in bipolar disorder.
Researchers assessed the total effect of bipolar disorder and major depression on cognitive function in adults between 40 and 69 years old and measured the effects mediated by psychotropic drug use and cardiometabolic disease.
The combination of memantine with escitalopram was linked to improved cognition in older patients with major depressive disorder.
Linkage to office-based buprenorphine treatment reduced illicit opioid use and increased days of buprenorphine treatment in patients discharged from a short-term detoxification program.
Investigators noted a significant increase in the odds of concurrent and subsequent marijuana use in adolescents and young adults who used e-cigarettes.
The mobile application App4Independence may be a feasible solution to improve self-management in patients with schizophrenia spectrum disorders.
Approximately one in five patients with major depressive disorder experienced an episode of high or fluctuating suicidal ideation despite treatment with nortriptyline or escitalopram.
Cariprazine significantly reduced mixed features in patients with bipolar I disorder.
Riluzole was overall well tolerated and associated with nonsignificant but positive effects in multiple psychiatric disorders, including depression and obsessive-compulsive disorder.
A short-term cognitive behavioral therapy program was associated with improvements in self-reported symptoms, time spent online, and psychosocial functioning.
Use of acetylcholinesterase inhibitors to manage dementia-related behavioral and psychological symptoms in people with Alzheimer disease may reduce the need for psychotropic medications.
Anticonvulsant mood stabilizers were not linked to a greater risk for placenta-mediated complications or preterm birth.
Chronic disease burden and baseline symptom severity were identified as consistent risk factors for negative depression trajectories in older adults.
Every 10-ng/mL increase in serum 25-hydroxyvitamin D was associated with a 12% decrease in the risk for depression in older adults.
Treatment with benzodiazepines for less than 3 months may not decrease the cognitive function of patients with major depressive disorder who are also prescribed antidepressants.
Augmentation of sertraline with eicosapentaenoic acid did not result in improved symptoms in patients with major depressive disorder and either a diagnosis of or at risk for coronary heart disease.
Adult patients with treatment-resistant depression showed a favorable improvement in symptoms after a course of esketamine twice-weekly for 28 days.
Latest News Your top articles for Friday
Haymarket Medical NetworkTop Picks